US pharmaceutical multinational Bristol Myers Squibb has opened its $1bn Cruiserath Biologics facility in north Dublin.
Some 450 people will be employed at the 125-acre manufacturing campus, which has the capacity to meet the demand for the company's existing biologics products and expected demand for products currently in development.
The site features science and technology labs as well as a warehouse and cryogenics logistics facility, which will facilitate commercial testing, release, development and manufacturing of biologics drugs substance.
The opening was attended by Bristol Myers Squibb CEO Giovanni Caforio, executive vice-president of global development and supply Karin Shanahan, and site general manager Pádraig Keane, who said:
“It is a proud day at Cruiserath Biologics as we celebrate the opening of our site with the presence of our global leadership team.
In Association with
"Biologics manufacturing is a highly complex, sensitive process, truly unique – from manufacture, to package, storage, and transit to reach our patients.
"This requires a commitment from each employee, across every department as well as collaboration across our network. Our people are truly committed to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. Our thriving Irish operation plays a critical role in the BMS network.”
Bristol Myers Squibb established operations in Ireland in 1964 with the opening of its active pharmaceutical ingredient plant in Swords, and its biologics drug substance manufacturing facility is also the certification site for all its drug products in the EU.
The group has a global biologics laboratory in Ireland that is responsible for release testing for all commercial biologic drug products, and its global headquarters for external manufacturing is located at Blanchardstown Corporate Park, along with its European treasury centre, commercial operations and market supply operations teams.
There's also Bristol Myers Squibb distribution centre in Shannon. The company produces pharmaceuticals and biologics for cancer, HIV/AIDS, cardiovascular disease, diabetes and other conditions.
In 2021, BMS grew revenues 9% to $46.4bn, with net income of $7bn. The company employs some 32,000 people worldwide, with assets of $109.3bn and equity of $36bn.
Image: Bristol Myers Squibb CEO Giovanni Caforio, executive vice-president of global development and supply Karin Shanahan, and site general manager Pádraig Keane
